All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know ALL.
The ALL Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy
Introducing
Now you can personalise
your ALL Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe ALL Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the ALL Hub cannot guarantee the accuracy of translated content. The ALL Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The ALL Hub is an independent medical education platform, sponsored by Jazz Pharmaceuticals, Amgen, and Pfizer. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
About the ALL Hub
The ALL Hub is an open-access online resource, dedicated to providing balanced, credible, and up-to-date medical education on acute lymphoblastic leukemia (ALL). Our aim is to enhance knowledge in ALL, through the multichannel dissemination of global advances related to its classification, diagnosis, treatment, and management.
The ALL Hub shares new data, evidence-based articles, therapy approvals, expert opinions, and international congress coverage to treatment teams and researchers around the world.
Vision
For every treatment team and researcher to have instant access to expert opinions and the latest evidence-based information in ALL, to aid in treatment decisions and improve the lives of patients with ALL globally.
Mission
The ALL Hub is the solution for a time-stretched HCP to easily access impactful information that expedites learning and empowers their treatment decisions. Informed by patients, curated by world leaders and endorsed by expert societies the ALL Hub supports HCPs worldwide.
Partnerships
The ALL Hub was founded in partnership with the European School of Haematology (ESH). ESH is a not-for-profit institution for the dissemination of information and lifelong learning founded in 1985 to promote and facilitate access to state-of-the-art and cutting-edge knowledge in hematology and related disciplines at the European level. ESH conferences present state-of-the-art science and insight into new developments in the fields of basic, clinical, and therapeutic research in hematology.
Brought to you by SES (scientific Education Support)
Independent medical education (IME), informed by patients, curated by world leaders, endorsed by expert societies. SES supports healthcare professionals and patients worldwide with up-to-date, accessible, and impactful educational content. Our hubs tackle information overload, providing a comprehensive central resource for healthcare professionals (HCPs) in specific disease areas that keep them up-to-date with the latest therapeutic news and world leading opinions. Endorsed by expert societies, and a member of the gCMEp, our platforms ensure credibility and trust. By identifying and filling knowledge gaps in easily digestible formats, we facilitate continuous learning, leading to improved patient outcomes.